...
首页> 外文期刊>Future oncology >Circulating miRNAs as new blood-based biomarkers for solid cancers
【24h】

Circulating miRNAs as new blood-based biomarkers for solid cancers

机译:循环miRNAs作为新的基于血液的实体癌生物标志物

获取原文
获取原文并翻译 | 示例

摘要

miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression. miRNAs' ability to inhibit translation of oncogenes and tumor suppressor genes implies they have an involvement in carcinogenesis. Specific miRNA expression signatures have been identified in a variety of human cancers. More recently, occurrence of miRNAs in the blood serum and plasma of humans has been repeatedly observed. miRNA levels in serum and plasma are more stable, reproducible and consistent among individuals of the same species in comparison with other circulating nucleic acids. Circulating miRNAs have been successfully evaluated in a wide range of solid cancers as promising novel noninvasive biomarkers of early disease onset or relapse. Here we describe the origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard, including breast, colorectal, lung and prostate cancer.
机译:miRNA是转录后调节基因表达的短非编码RNA。 miRNA抑制癌基因和抑癌基因翻译的能力暗示它们参与了癌变。在多种人类癌症中已经确定了特定的miRNA表达特征。最近,已经反复观察到人类的血清和血浆中miRNA的出现。与其他循环核酸相比,同一物种的个体中血清和血浆中的miRNA水平更稳定,可重现且一致。循环中的miRNA已在多种实体癌中成功评估,它们是早期疾病发作或复发的有希望的新型非侵入性生物标记。在这里,我们描述了循环miRNA的起源,其巨大稳定性的原理和拟议的功能,并全面总结了针对其在这方面最常研究的癌症类型(包括乳腺癌,结肠直肠癌,肺癌和前列腺癌)中的意义的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号